AR058985A1 - Diaril piperidinas como moduladores de cb1. - Google Patents

Diaril piperidinas como moduladores de cb1.

Info

Publication number
AR058985A1
AR058985A1 ARP070100120A ARP070100120A AR058985A1 AR 058985 A1 AR058985 A1 AR 058985A1 AR P070100120 A ARP070100120 A AR P070100120A AR P070100120 A ARP070100120 A AR P070100120A AR 058985 A1 AR058985 A1 AR 058985A1
Authority
AR
Argentina
Prior art keywords
substituted
groups
aryl
unsubstituted
alkyl
Prior art date
Application number
ARP070100120A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR058985A1 publication Critical patent/AR058985A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)

Abstract

Son utiles para tratar enfermedades, trastornos o afecciones tales como síndrome metabolico (por ej., obesidad, circunferencia de la cintura, perfil de lípidos y sensibilidad a la insulina), trastornos neuroinflamatorios, trastornos cognitivos, psicosis, comportamiento adictivo, trastornos gastrointestinales y afecciones cardiovasculares. Reivindicacion 1: Un compuesto de formula (1) o una sal, solvato o éster aceptable para uso farmacéutico del mismo, donde: A es -CH2- o -C(O)-; R1 se selecciona del grupo que consiste en H, -N(R4)(R5), heterociclilo no sustituido, heterociclilo sustituido con uno o más grupos X, -N3 y -O-R7; R2 se selecciona del grupo que consiste en H, -(C(R6)2)p-arilo, cicloalquilalquilo, cicloalquilalquilo sustituido con Z, -(C(R6)2)q-heterociclilo, -(C(R6)2)p-S(O)2-heterociclilo y -C(R6)2-O-R7, donde la porcion arilo de dicho -C(R6)2-arilo de R2 es no sustituida o está sustituida con uno o más grupos Y, donde la porcion heterociclilo de dicho - (C(R6)2)p-S(O)2-heterociclilo de R2 es no sustituida o está sustituida con uno o más grupos X, donde la porcion heterociclilo de dicho -(C(R6)2)g-heterociclilo de R2 es no sustituida o está sustituida con uno o más grupos X; R3 se selecciona del grupo que consiste en H, -C(R6)2-arilo, -C(R6)2-O-R7, -(C( R6)2)q-C(O)N(R12)2, -(C(R6)2)p-N(R9)-C(O)-(C( R6)2)q-R16, -(C(R6)2)q-S(O)2-N-(R9)-(C(R6)2)q-R15, -(C(R6)2)q-N(R9)-S(O)2-(C(R6)2)q-R15,y -C(R6)2)q-N(R8)2, donde la porcion arilo de dicho - C(R6)2-arilo de R3 es no sustituida o está sustituida con uno o más grupos Y; con las siguientes salvedades independientes:(i) al menos uno de R1, R2 y R3 no es H; (ii) cuando R1 es -OH, al menos uno de R2 y R3 no es H; y (iii) cuando A es -C(O)- , al menos uno de R2 y R3 no es H; o, R2 y R3 junto con el átomo de carbono anular al que se encuentran unidos forman un anillo heterociclilo no sustituido o un anillo heterociclilo sustituido con uno o más grupos X; R4 se selecciona del grupo que consiste en H, -C(O)-alquilo y alquilo; R5 se selecciona del grupo que consiste en -(C(R6)2)m-G, -S(O)2-alquilo, -S(O)2-cicloalquilo, alquilo, -S(O)-cicloalquilo, -C(O)-cicloalquilo, -S(O)2-arilo, S(O)2-(C(R6)2)m-arilo, -S(O)2-heteroarilo, -C(O)- alquilo, -C(O)-arilo, -C(O)-O-alquilo, -C(O)-O-arilo, -C(O)-(C(R6)2)m-arilo, -C(O)-cicloalquilen arilo, -C(O)-heteroarilo, -C(O)-heteroarilalquilo, -C(O)-(C(R6)2)m-O-arilo, -C(O)-(cicloalquilo benzofusionado), -S(O)2-(heterociclilo benzofusionado), C(O)-N(R9)-(C(R6)2)m-arilo, -C(O)-N(R9)-arilo, cicloalquilo, cicloalquilo benzofusionado, arilo no sustituido, arilo sustituido con uno o más grupos Y, heterociclilo no sustituido, y heterociclilo sustituido con uno o más grupos X, donde la porcion arilo o heteroarilo de dicho -S(O)2-arilo, -S(O)2-(C(R6)2)m- arilo, -S(O)2-heteroarilo, -C(O)-arilo, -C(O)-(C(R6)2)m-arilo, -C(O)-cicloalquilen arilo, -C(O)-heteroarilo, -C(O)-(C(R6)2)m-O-arilo, C(O)-N(R9)(C(R6)2)m-arilo o -C(O)- N(R9)-arilo de R5 es no sustituida o está sustituida con uno o más grupos Y; donde la porcion heterociclilo de -S(O)2-(heterociclilo benzofusionado) arilo de R5 es no sustituida o está sustituida con uno o más grupos X; cada R6 se selecciona en forma independiente del grupo que consiste en H y alquilo; R7 se selecciona del grupo que consiste en H, alquilo, heteroarilo no sustituido y heteroarilo sustituido con uno o más grupos Y, arilo no sustituido, y arilo sustituido con uno o más grupos Y; cada R8 se selecciona en forma independiente del grupo que consiste en H, alquilo, arilalquilo, heteroarilalquilo, arilo no sustituido, heteroarilo no sustituido, -C(O)-alquilo, -C(O)-arilo, -C(O)-cicloalquilo, -C(O)N(R9)2, -S(O)2-arilo, - S(O)2-heteroarilo, -SO2N(R9)2, -S(O)2-cicloalquilo, arilo y heteroarilo sustituido con uno o más grupos Y, y -S(O)2-alquilo, donde la porcion arilo de dicho arilalquilo, -C(O)-arilo o -S(O)2-arilo y la porcion heteroarilo de dicho heteroarilalquilo, -S(O)2-heteroarilo de R8 es no sustituida o está sustituida con uno o más grupos Y, donde la porcion alquilo de dicho arilalquilo y heteroarilalquilo es no sustituida o está sustituida con uno o más grupos X con la salvedad que el grupo X sustituido en dichas porciones alquilo NO sea Cbz o Boc; cada R9 se selecciona en forma independiente del grupo que consiste en H, alquilo, haloalquilo, hidroxialquilo, cicloalquilo, arilo no sustituido y heteroarilo no sustituido; cada R12 se selecciona en forma independiente del grupo que consiste en H, alquilo, cicloalquilalquilo, -(C(R6)2)q-C(O)R13, benzoheterociclilo, benzocicloalquilo, -(C(R6)2)q-N(R9)-C(O)R13 , (C(R6)2)q-N(R14)2, arilaIquilo, heteroarilalquilo, HO- alquil-, alquil-O-, aril-O-, Y-alquilenil-O-, W-O-alquilenilo, heterociclilalquilo, cicloalquilo no sustituido, cicloalquilo sustituido con uno o más grupos X, heterociclilo no sustituido, heterociclilo sustituido con uno o más grupos X, heteroarilo no sustituido, heteroarilo sustituido con uno o más grupos Y, arilo no sustituido y arilo sustituido con uno o más grupos Y, y donde la porcion arilo y heteroarilo de dicho arilalquilo y heteroarilalquilo es no sustituida o está sustituida con uno o más grupos Y, donde la porcion alquilo de dicho cicloalquilalquilo, arilalquilo y heteroarilalquilo es no sustituida o está sustituida con uno o más grupos X, con la salvedad de que el grupo X sustituido en dichas porciones de alquilo NO sea Cbz o Boc, donde el cicloalquilo de dicho cicloalquilalquilo es no sustituido o está sustituido con uno o más grupos X, donde la porcion benzo de dicho benzoheterociclilo puede estar sustituida en forma opcional con uno o más grupos Y, y la porcion heterociclilo de benzoheterociclilo puede estar sustituida en forma opcional con uno o más grupos X, donde la porcion benzo de dicho benzocicloalquilo puede estar sustituida en forma opcional con uno o más grupos Y, y la porcion cicloalquilo de benzocicloalquilo puede estar sustituida en forma opcional con uno o más grupos X; con las siguientes salvedades que para -N(R14)2 de R12, los dos grupos R14, con el átomo de nitrogeno del anillo al que se ven unidos, forman un anillo heterociclilo no sustituido o un anillo heterociclilo sustituido con uno o más grupos X; cada R13 se selecciona en forma independiente del grupo que consiste en H, alquilo, cicloalquilalquilo, arilalquilo, heteroarilalquilo, HO-alquil-, alquil-O-, aril-O-, cicloalquilo no sustituido, cicloalquilo sustituido con uno o más grupos X, heterociclilo no sustituido, heterociclilo sustituido con uno o más grupos X, heteroarilo no sustituido, heteroarilo sustituido con uno o más grupos Y, arilo no sustituido y arilo sustituido con uno o más grupos Y; donde la porcion arilo y heteroarilo de dicho arilalquilo y heteroarilalquilo es no sustituida o está sustituida con uno o más grupos Y, donde la porcion alquilo de dicho cicloalquilalquilo, arilalquilo y heteroarilalquilo es no sustituida o está sustituida con uno o más grupos X con la salvedad de que el grupo X sustituido en dicha porcion alquilo NO sea Cbz o Boc, donde el cicloalquilo de dicho cicloalquilalquilo es no sustituido o está sustituido con uno o más grupos X; cada R14 se selecciona en forma independiente del grupo que consiste en H, Boc, alquilo no sustituido, alquilo sustituido con uno o más grupos X, cicloalquilo no sustituido, cicloalquilo sustituido con uno o más grupos Y, arilo no sustituido, arilo sustituido con uno o más grupos Y, heterociclilo, heteroarilo no sustituido, heteroarilo sustituido con uno o más grupos Y; cada R15 se selecciona en forma independiente del grupo que consiste en H, alquilo, - N(R4)(R5), (C(R6)2)q-N(R14)2, alquilenil-CF3, -CF3, cicloalquilalquilo, cicloalquilo no sustituido, cicloalquilo sustituido con uno o más grupos X, heterociclilo no sustituido, heterociclilo sustituido con uno o más grupos X, benzoheterociclilo, benzocicloalquilo, heteroarilo no sustituido, heteroarilo no sustituido con uno o más grupos Y, arilo no sustituido y arilo sustituido con uno o más grupos Y, donde la porcion alquilo de dicho cicloalquilalquilo es no sustituida o está sustituida con uno o más grupos X, con la salvedad de que el grupo X sustituido en dicha porcion alquilo NO sea Cbz o Boc, donde el cicloalquilo de dicho cicloalquilalquilo es no sustituido o está sustituido con uno o más grupos X, donde la porcion benzo de dicho benzoheterociclilo puede estar sustituida en forma opcional con uno o más grupos Y y la porcion heterociclilo de benzoheterociclilo puede estar sustituida en forma opcional con uno o más grupos X, donde la porcion benzo de dicho benzocicloalquilo puede estar sustituida en forma opcional con uno o más grupos Y y la porcion cicloalquilo de benzocicloalquilo puede estar sustituida en forma opcional con uno o más grupos X; cada R16 se selecciona en forma independiente del grupo que consiste en H, alquilo, cicloalquilalquilo, -(C(R6)2)p-C(O)R13, -(C(R6)2)p-N(R9)-C(O)R13, -(C(R6)2)p-N(R14)2, arilalquilo, heteroarilalquilo, HO-alquil-, alquil-O-, aril-O-, cicloalquilo no sustituido, cicloalquilo sustituido con uno o más grupos X, heterociclilo no sustituido, heterociclilo sustituido con uno o más grupos X, heteroarilo no sustituido, heteroarilo sustituido con uno o más grupos Y, arilo no sustituido y arilo sustituido con uno o más grupos Y, y donde la porcion arilo y heteroarilo de dicho arilalquilo y heteroarilalquilo es no sustituida o está sustituida con uno o más grupos Y, donde la porcion alquilo de dicho cicloalquilalquilo, arilalquilo y heteroarilalquilo es no sustituida o está sustituida con uno o más grupos X, con la salvedad de que el grupo X sustituido en dicha porcion alquilo NO sea Cbz o Boc, donde el cicloalquilo de dicho cicloalquilalquilo es no sustituido o está sustituido con uno o más grupos X, para -N(R14)2, los dos grupos R14, con el átomo de nitrogeno del anillo al que se encuentran unidos, forman un anillo heterociclilo no sustituido o un anillo heterociclilo sustituido con uno o más grupos X; G se seleccion
ARP070100120A 2006-01-13 2007-01-11 Diaril piperidinas como moduladores de cb1. AR058985A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75909106P 2006-01-13 2006-01-13
US80299006P 2006-05-24 2006-05-24

Publications (1)

Publication Number Publication Date
AR058985A1 true AR058985A1 (es) 2008-03-05

Family

ID=38255056

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100120A AR058985A1 (es) 2006-01-13 2007-01-11 Diaril piperidinas como moduladores de cb1.

Country Status (8)

Country Link
US (1) US20070203183A1 (es)
EP (1) EP1987000A2 (es)
JP (1) JP2009525954A (es)
AR (1) AR058985A1 (es)
CA (1) CA2637057A1 (es)
MX (1) MX2008009060A (es)
TW (2) TW200738633A (es)
WO (1) WO2007084319A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2589483C (en) 2004-12-03 2013-10-29 Schering Corporation Substituted piperazines as cb1 antagonists
CA2637565A1 (en) * 2006-01-18 2007-07-26 Schering Corporation Cannibinoid receptor modulators
TW200831080A (en) 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
JP2010523540A (ja) * 2007-04-03 2010-07-15 ファイザー・インク スルホンアミドおよびその医薬組成物
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
RU2010102478A (ru) * 2007-06-28 2011-08-10 Интэрвэт Интэрнэшнл Б.Ф. (NL) Замещенные пиперазины как антагонисты св1
WO2009005671A2 (en) * 2007-06-28 2009-01-08 Schering Corporation Substituted piperazines as cb1 antagonists
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
MX2010004929A (es) 2007-11-05 2010-05-27 Novartis Ag Derivados de 4-bencil-amino-1-carboxi-acil-piperidina como inhibidores de proteina de transferencia de colesterol-ester (cetp) utiles para el tratamiento de enfermedades tales como hiperlipidemia o arteriosclerosis.
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010081851A1 (en) 2009-01-14 2010-07-22 Genoscience Pharma Piperidin-4-ylpiperazine compounds for the treatment of hcv infection
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
JO2998B1 (ar) * 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
PL2771003T3 (pl) 2011-10-28 2017-10-31 Lumena Pharmaceuticals Llc Inhibitory ponownego wykorzystania kwasów żółciowych do leczenia pediatrycznych cholestatycznych chorób wątroby
CN104023718B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂
MX2015013196A (es) 2013-03-15 2016-04-15 Lumena Pharmaceuticals Inc Inhibidores de reciclaje de acidos biliares para el tratamiento de la enfermedad de reflujo gastroesofagico y esofago de barrett.
CA2907230A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
CN114096268A (zh) 2019-02-12 2022-02-25 米鲁姆制药公司 用于增加患有胆汁淤积性肝病的儿科受试者的生长的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63264458A (ja) * 1986-12-03 1988-11-01 Tanabe Seiyaku Co Ltd ラクタム誘導体
FI875101A (fi) * 1986-12-03 1988-06-04 Tanabe Seiyaku Co Laktamderivat och preparat innehaollande dessa.
US5332817A (en) * 1990-01-04 1994-07-26 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles
US5580883A (en) * 1990-03-26 1996-12-03 Takeda Chemical Industries, Ltd. Aminobenzene compounds to prevent nerve cell degradation
US5185349A (en) * 1991-03-08 1993-02-09 Warner-Lambert Company Substituted amide ACAT inhibitors lactone derivatives
US5234895A (en) * 1992-06-19 1993-08-10 Imperial Chemical Industries Plc Arylpyridone herbicides
US20020128476A1 (en) * 1996-08-08 2002-09-12 Smithkline Beecham Corporation Inhibitors of cysteine protease
BR9808502A (pt) * 1997-05-08 2000-05-23 Smithkline Beecham Corp Inibidores de protease
US20010006972A1 (en) * 1998-04-21 2001-07-05 Stephen A. Williams Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
CA2347769A1 (en) * 1998-12-18 2000-06-22 Dean A. Wacker 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
US7071213B2 (en) * 2001-11-14 2006-07-04 Schering Corporation Cannabinoid receptor ligands
US20030171588A1 (en) * 2002-03-07 2003-09-11 Kahl Jeffrey D. 1,2-disubstituted-6-oxo-3-phenyl-piperidine-3-carboxamides and combinatorial libraries thereof
US20040167185A1 (en) * 2003-01-16 2004-08-26 Geetha Shankar Methods of treating conditions associated with an Edg-3 receptor

Also Published As

Publication number Publication date
US20070203183A1 (en) 2007-08-30
WO2007084319A3 (en) 2007-09-20
WO2007084319A2 (en) 2007-07-26
MX2008009060A (es) 2008-09-26
CA2637057A1 (en) 2007-07-26
EP1987000A2 (en) 2008-11-05
TW201031636A (en) 2010-09-01
TW200738633A (en) 2007-10-16
JP2009525954A (ja) 2009-07-16

Similar Documents

Publication Publication Date Title
AR058985A1 (es) Diaril piperidinas como moduladores de cb1.
AU2009206075B2 (en) 6-and 7-amino isoquinoline compounds and methods for making and using the same
AU2015342887B2 (en) Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
AU2009200430B2 (en) Thiophene derivatives as antiviral agents for flavivirus infection
AR040351A1 (es) Derivados de quinuclidina-amida, composicion farmaceutica, procedimiento de preparacion del compuesto y su uso para fabricar medicamentos
JP5237094B2 (ja) 置換された１−オキサ−３，８−ジアザスピロ［４．５］−デカン−２−オン化合物及び医薬の製造へのその使用
CN105272904B (zh) N-苯基酰胺类化合物及其应用
AR064459A1 (es) Derivados de sulfonamida
NO20085140L (no) Nye indazolderivater som har spiro ringstruktur i sidekjede
WO2005079791A1 (en) Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
CN105980353A (zh) RORγ调节剂
AR063331A1 (es) Derivados de biaril eter urea y composiciones farmaceuticas
RS52562B (en) (3-ARIL-PIPERAZINE-1-IL) DERIVATI 6,7-DIALCOKSIQUINZOLINE, 6,7-DIALCOKSIFTALAZINE I
KR20140070550A (ko) 항암제로서의 삼환식 화합물
AR075597A1 (es) Derivados de indol como antagonistas de receptores crth2, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del asma y otras enfermedades alergicas .
Pasquinucci et al. Evaluation of N-substitution in 6, 7-benzomorphan compounds
WO2003041708A1 (en) Benzimidazoles useful as protein kinase inhibitors
AR061486A1 (es) Derivados de 2-pirazinacarboxamida
CO6210701A2 (es) Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-a]imidazol-3-carboxilico
WO2011088187A1 (en) Compounds and methods
WO2006133588A1 (en) ARYL UREA COMPOUNDS AS β-SECRETASE INHIBITORS
CA2901493A1 (en) Tricyclic heterocycles as anticancer agents
WO2007079593A8 (en) Novel melatonin ligands having antidepressant activity as well as sleep inducing properties
CN104530014A (zh) 2-氧代-1,2-二氢苯并[cd]吲哚-6-磺酰胺类化合物及其组合物和应用
PE20090325A1 (es) Nuevos compuestos ligandos del receptor de la adenosina a3

Legal Events

Date Code Title Description
FA Abandonment or withdrawal